(Reuters) - A combination of two drugs developed by AstraZeneca Plc, olaparib and cediranib, was shown in a mid-stage study to nearly double the length of time certain ovarian cancer patients lived without their disease getting worse. After spurning a $118 billion takeover approach from Pfizer Inc, Britain's AstraZeneca is aiming to show investors at this weekend's meeting of the American Society of Clinical Oncology in Chicago that its pipeline of cancer drugs offers an opportunity for future sales growth. The 90-patient study is the first to look at a drug that blocks a cell repair enzyme known as PARP, olaparib, together with a drug designed to prevent the formation of blood vessels needed by tumors, cediranib, for treating ovarian cancer. Patients in the trial had recurrent cancer that had initially responded to treatment with platinum-based chemotherapy or had cancer related to the BRCA gene.
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/1rt3kE8
No comments:
Post a Comment